Treatment of Grass Pollen-Induced Hay Fever with Intranasal Budesonide.

Publisher Website
Google Scholar
Abstract
The clinical effects of intranasal budesonide (16.alpha., 17.alpha.-(22 R,S)-propylmethylenedioxypregana-1-4-diene-11.beta. 21 diol-3, 20 dione)), a new non-halogenated glucocorticoid, were evaluated in a double-blind comparison with placebo, in patients with pronounced hay fever. Aerosolized budesonide, using a daily dosage of either 400 .mu.g or 200 .mu.g, showed a highly significant reduction in the nasal symptoms compared with placebo. No significant difference could be demonstrated between the effects of 400 .mu.g and 200 .mu.g per day, suggesting that the lower dosage is adequate. No significant effect on the eye symptoms and no fall in plasma cortisol values were observed with either dosage. Only mild side effects were reported.